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Abstract
Background: Aldehyde dehydrogenase 1 (ALDH1) is widely used as a specific cancer stem cell marker in a variety
of cancers, and may become a promising target for cancer therapy. However, the role of its expression in tumor
cells and the microenvironment in different cancers is still controversial.
Methods: To clarify the clinicopathological effect of ALDH1 expression in ovarian carcinoma, a series of 248 cases
of paraffin-embedded formalin fixed ovarian carcinoma tissues with long term follow-up information were stud-
ied by immunohistochemistry.
Results: The immunostaining of ALDH1was variably detected in both tumor cells and the stromal cells, although
the staining in tumor cells was not as strong as that in stromal cells. Statistical analyses showed that high ALDH1
expression in tumor cells was significantly associated with histological subtypes, early FIGO stage, well
differentiation grade and better survival probability (p < 0.05). The expression of ALDH1 in the stromal cells had
no clinicopathological associations in the present study (p > 0.05).
Conclusioms: High expression of cancer stem cell marker ALDH1 in ovarian carcinoma cells may thus portend a
favorable prognosis, but its expression in tumor microenvironment may have no role in tumor behavior of
ovarian carcinomas. More studies are warranted to find out the mechanisms for this.
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Background
Ovarian carcinoma remains the most mortality in gyneco-
logic tumors [1]. There are 225,000 new cases diagnosed
and 140,000 deaths of ovarian carcinoma annually world-
wide [1]. The standard treatment remains surgery followed
by platinum-based chemotherapy [2]. Acquired drug resist-
ance and cancer recurrence become the main hurdles for
ovarian carcinoma treatment currently [3]. As a result, new
reagents targeting the chemo-resistant cells are needed.
Aldehyde dehydrogenases (ALDH) are a group of en-
zymes that catalyse dehydrogenation of aldehydes to their
corresponding carboxylic acids. To date, nineteen ALDH
genes which encode several isozymes have been identified
in human genome. Aldehyde dehydrogenase 1 (ALDH1)
gene encodes a cytosolic isoform localized in the cytoplasm
and ALDH2 gene encodes a mitochondrial isoform located
in mitochondrial matrix. Nevertheless, ALDH1 in human
is not limited to the metabolic enzyme. It should be noted
that ALDH1 is involved in regulating cell differentiation
[4, 6], proliferation and motility [6, 7]. Its regulation role in
stem cells is particularly through the retinoid signaling
pathway [8, 9]. It is also reported that inhibition of
ALDH1-mediated retinoid signaling impairs human fetal
islet cell differentiation and survival [5]. ALDH1 may
contribute to tumor initiation and chemoresistance [10]. In
addition, it is regarded as a cancer stem cell (CSC) marker
in a variety of cancers [11], including ovarian carcinoma
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[12, 13], lung cancer [14, 15], rectal cancer [16] and others
[17, 18]. CSCs are a subpopulation of cancer cells which
have the properties of self-renewal and tumorigenicity, and
thus may play a key role in cancer metastasis, chemoresis-
tance and relapse. Therapeutic modalities targeting CSCs
are becoming a hot topic in recent years to prevent cancer
relapse and vastly improve cancer survival probability [19].
Targeting CSC specific markers is one of the most import-
ant and easily achievable ways to identify putative CSCs.
ALDH1, as a largely used stem cell marker in recent CSC
studies, is mostly regarded as a poor prognostic factor in a
variety of cancers [17, 18, 20, 21].
However, it remains debatable whether ALDH1 as a
single marker can be sufficient to identify CSCs [22].
Futhermore, different isoforms of ALDH1 may serve
variable roles in CSCs [23]. To date, the predictive role
of ALDH1 in ovarian carcinoma cells and stromal cells
are still obscure. While Chang et, al. found it was signifi-
cantly associated with favorable clinical outcomes and
better survivals in 442 cases of primary ovarian carcin-
oma patients [24], others insisted that it is an unfavor-
able prognostic factor in ovarian carcinomas [20, 21].
To further understand the prognositic role of ALDH1
in ovarian carcinoma cells and the stromal cells, we ran-
domly enrolled 248 cases of primary ovarian carcinoma
and investigated the expression of ALDH1 in these
tissues by immunohistochemistry (IHC). The staining of
ALDH1 in both carcinoma cells and stromal cells were
evaluated and their associations with clinicalpathological
parameters were analyzed by SPSS software.
Methods
Ethics statement
This study was approved by The Regional Committee for
Medical Research Ethics South of Norway (S-06277a), The
Social- and Health Directorate (06/3280) and The Data
Inspectorate (06/5345).
Clinical samples
Two-hundred and forty-eight surgically removed ovarian
carcinoma samples were randomly enrolled in this study.
All patients were diagnosed and operated at The
Norwegian Radium Hospital, Oslo University Hospital
during 1983 to 2000. The ages of the patients at diagno-
sis range from 19 to 89 years, with a median of 58 years.
The patients were followed up until January 1st 2012. All
the patients were clinically staged by the criteria of
International Federation of Gynecology and Obstetrics
(FIGO) stage [25]. The primary tumors were histologically
graded as well, moderately and poorly differentiated ac-
cording to WHO recommendations by two of the authors
(J.M. and Z.S.) [26]. Disease progression was determined
based on the definitions outlined by the Gynecologic
Cancer Intergroup [27].
IHC
Three-micrometres sections made from formalin-fixed par-
affin embedded tissues were immunostained using
Dako Envision™ FLEX+ system (K8012; Dako, Glostrup,
Denmark) and the Dako Autostainer. Paraffin sections
were deparaffinized and epitopes unmasked in PT-link
with low pH target retrieval solution (Dako), and then
blocked with peroxidase blocking (Dako) for 5 min. The
slides were incubated at 4 °C overnight with mouse anti-
human ALDH1 antibody (1: 3000, 83 ng IgG1/ml, Clone 44,
Lot. No. 03817, BD Transduction Laboratories™), followed up
by incubation with mouse linker for 15 min and HRP for
30 min at room temperature. Slides were then stained with 3,
3′-diaminobenzidine tetrahydrochloride (DAB) for 10 min
and counter-stained with hematoxylin, dehydrated, and
mounted in Richard-Allan Scientific Cyto seal XYL
(Thermo Scientific, Waltham, MA, USA). Known ALDH1-
positive human vulvar squamous cell carcinoma slide [28]
was used as positive control. Mouse myeloma protein of
the same subclass and concentration as the primary mouse
anti-ALDH1 antibody was used for negative control.
IHC scoring system
Allred scoring system [29, 30] was used for evaluating
ALDH expression levels in ovarian carcinoma tissues. The
ovarian carcinoma cells and the stromal cells were scored
separately. The intensity of the immunohistochemical
staining was scaled by 0 to 3 and the percentage of immu-
nostaining cells was scaled by 0 to 5 (Table 1). The sum of
intensity score and percentage score was seen as total
score, which ranged from 0 to 8. The slide was regarded
as ALDH negative, low expression and high expression
when the total score is 0, 1 to 6 and 7 to 8, respectively.
Examination of immunostaining was performed by two
Table 1 The criteria of Allred scoring system used for evaluating
ALDH1 expression in the ovarian carcinoma cells and the stromal
cells in our study
1. The criteria of intensity scoring system
Intensity
Score
0 1 2 3
Negative Weak Moderate Strikingly positive at low
magnitude
2. The criteria of percentage scoring system
Percentage
Score
0 1 2 3 4 5







aThe total score was obtained by adding the percentage score to intensity
score. It ranges from 0 to 8
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independent observers (RHuang and ZS), and all the cases
were verified by another pathologist (JMN).
Statistical analyses
SPSS software (version 18.0) was used for survival ana-
lysis and the analyses of the associations between
ALDH1 expression and the clinical outcomes. Associa-
tions between categorical variables were assessed by
Chi-square tests (Pearson and linear-by-linear as appro-
priate). Survival analysis was performed using the
Kaplan-Meier method, and groups were compared with
log-rank tests. Multivariate analysis was performed using
Cox Regression method. Patients alive on the last
follow-up date without recurrence were censored. For all
the analyses, associations were considered to be signifi-
cant if the p value was < 0.05.
Results
ALDH1 was variably detected in clinical ovarian
carcinoma samples
Immunoreactive ALDH1 was variably detected in the
ovarian carcinoma cells and the stromal cells in all the
ovarian primary tumor samples (Fig. 1). Endothelial cells
of blood vessel were always positive for ALDH1. The
immunostaining was limited to cytoplasm and cell
membrane. Out of the total 248 samples, 98 cases were
negative in tumor cells for ALDH1, and 111 cases had a
low expression level and 39 cases had a high expression
level (Table 2). Generally, the tumor cells from well-
differentiated carcinomas tended to highly expressed
ALDH1 and those from poor-differentiated carcinomas
tended to express ALDH1 lowly. Compared with the
tumor cells, ALDH1 expression in the stromal cells was
generally rather strong. The numbers of negative, low
expression and high expression of ALDH1 in the stromal
cells were 13 cases, 61 cases and 174 cases, respectively
(Table 3).
ALDH1 expression was not associated with the ages
The ages at diagnosis were divided into five groups for
the association analyses: ≤ 39, 40–49, 50–59, 60–69
and ≥ 70 years. The expression of ALDH1 in ovarian
carcinoma cells was not significantly different (p > 0.05,
linear by linear association). There was no significant
difference between each age group for ALDH1 expres-
sion in the stromal cells as well (p > 0.05, linear by lin-
ear association).
ALDH1 expression in ovarian carcinoma cells was
associated with histological subtype
Ovarian carcinoma patients involved in our study were
diagnosed and verified as several subtypes by histology:
serous carcinoma, mucinous carcinoma, endometrioid
carcinoma, clear cell carcinoma, mixed epithelial tumor,
undifferentiated tumor and others. ALDH1 expression
in tumor cells tended to be negative or low in serous
carcinoma and clear cell carcinoma. There was signifi-
cant difference for the ALDH1 expression levels in
tumor cells between each histological subtypes, highest
in mucinous carcinoma (p < 0.001, Pearson Chi-Square
test, Table 2). However, the ALDH1 expression in stro-
mal cells had no significant differences between each
histological group (p > 0.05, Pearson Chi-Square test,
Table 3).
ALDH1 expression in ovarian carcinoma cells was
associated with early FIGO stage
FIGO stage, as the most popular clinically used stage cri-
teria is an important prognostic predictor in ovarian car-
cinomas [25]. High expression of ALDH1 in ovarian
carcinoma cells was significantly associated with early
FIGO stage (p < 0.05, linear by linear association,
Table 2). The percentage of high ALDH1 expression in
ovarian carcinoma cells distributes largely in FIGO stage
I (35.7 %) and II (22.2 %) than FIGO stage III (12.8 %)
and IV (12.7 %). However, no significant association be-
tween ALDH1 expression in tumor stromal cells and
FIGO stage was discoverd (p > 0.05, linear by linear asso-
ciation, Table 3).
ALDH1 expression in ovarian carcinoma cells was
associated with well differentiation grade
Differentiation grade stands for the malignant potential
in tumors. Well differentiated carcinomas are regarded
as low malignant potential and conversely poor differen-
tiated carcinomas as high malignant potential in ovarian
carcinomas [26]. In the well differentiated carcinoma
group the percentage of ALDH1 high expression cases
in tumor cells (31.6 %) was much higher than the per-
centage in the moderate differentiation group (11.3 %)
and the poor differentiation group (11.3 %), which was
in accordance with our general finding when evaluating
slides. The association between ALDH1 expression in
tumor cells and the differentiation grade was significant
(p < 0.05, linear by linear association, Table 2). Neverthe-
less, the ALDH1 expression in the stromal cells was not
associated with the differentiation grade (p > 0.05, linear
by linear association, Table 3).
ALDH1 expression in ovarian carcinoma cells was
associated with better survivals
There were totally 232 valid cases with full information
for the analyses of overall survival (OS) and progression
free survival (PFS). The median OS was 1.480 years with
95 % confidence interval (CI) of 1.076 years to 1.884 years.
The median PFS was 0.650 year and the 95 % CI was
0.507 year to 0.793 year.
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In the 232 patients, ALDH1 expression in tumor cells
was negative in 86 cases, low in 108 cases and high in 38
cases. The median OSs in the ALDH1 tumor-negative
group, tumor low-expression group and tumor high-
expression group were 1.440 years, 1.330 years and
3.000 years, respectively. The median PFSs in the above
three groups were 0.590 year, 0.580 year and 1.050 years,
respectively. Furthermore, ALDH1 expression in ovarian
carcinoma cells was significantly associated with better
OS and PFS by statistical analyses (p < 0.05, Kaplan-
Meier method, Fig. 2a, b).
Out of the 232 valid cases for survival analyses, ALDH1
expression in stromal cells was negative, low and high in
12 cases, 55 cases and 165 cases, respectively. The median
OSs in the ALDH1 stromal-negative group, stromal-low
group and stromal-high group were 1.320 years, 1.850 years
and 1.480 years, respectively. The median PFSs in the
above three groups were 0.980 year, 0.760 year and
Fig. 1 ALDH1 expression in ovarian carcinoma cells and stromal cells. a A poor differentiated ovarian carcinoma showed negative immunostaining in
tumor cells for ALDH1, while most of the stromal cells surrounding tumor cells were strongly positive (100×). b High magnitude was used in the same
case in A, showing clear negative tumor cells and positive stromal cells (400×). c Variable expression levels of ALDH1 in tumor cells were displayed in
a moderately differentiated ovarian carcinoma. The stromal cells were all positive (100×). d A part of figure (b) was enlarged, showing weakly positive
staining in most of the tumor cells and the staining was limited to the membrane and the cytoplasm (400×). e Tumor cells in a well differentiated
ovarian carcinoma were all strongly positive while the stromal cells were negative (100×). f High magnitude of a part of figure (E) displayed strongly
positive staining for ALDH1 in most of the epithelial tumor cells/hyperplasia epithelial cells (400×)
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0.610 year, respectively. ALDH1 expression in the stromal
cells was thus not significantly associated with OS and
PFS by statistical analyses (p > 0.05, Kaplan-Meier method,
Fig. 2 c, d).
ALDH1 expression in tumor cells is not independent risk
factor for overall survival
Multivariate analysis was performed using Cox Regres-
sion method based on the above clinicopathological
parameters and ALDH1 expression in tumor cells and
stromal cells (Table 4). Age at diagnosis, FIGO stage and
differentiation grade are independent risk factor for
overall survival in ovarian carcinomas (p < 0.05), while
other variables including histological subtypes, ALDH1
expression in tumor cells and ALDH1 expression in
stromal cells does not contribute to overall survival
independently (p > 0.05).
Discussion
Ovarian carcinoma is actually one of the most chemo-
sensitive solid malignancies [31], but it is still the most
lethal gynecologic malignancy worldwide. Although
most ovarian carcinoma cells are initially sensitive to
chemotherapy, there is always a small population cells
that always survives and initiates new tumors which
causes recurrence [31]. The verification of tumor hetero-
geneity further enhances the hypothesis of CSCs. Com-
pelling evidence has shown that ovarian carcinomas
with enriched CSCs exhibit aggressive features in vitro
and predict poor outcomes in patients [21, 32, 33].
Theoretically a high proportion of CSCs in tumor
should be correlated with poor prognosis. However, the
CSC markers are not always universal in a given tumor.
The candidates raised up to characterize ovarian CSCs
include CD44, epithelial cell adhesion molecule
Table 2 The associations of ALDH1 expression levels in ovarian carcinoma cells and the clinical and pathologic characteristics
ALDH1 IHC score in tumor cells p-value
1 (negative) 2 (low) 3 (high)
Number Total N 98 111 39
Age (years old):
≤39 16 5 (31.3 %) 6 (37.5 %) 5 (31.3 %)
40–49 41 20 (48.8 %) 15 (36.6 %) 6 (14.6 %) 0.940
50–59 64 20 (31.3 %) 34 (53.1 %) 10 (15.6 %)
60–69 72 28 (38.9 %) 35 (48.6 %) 9 (12.5 %)
≥70 39 13 (33.3 %) 18 (46.2 %) 8 (20.5 %)
missing 16
Histological subtype:
Serous carcinoma 163 67 (41.1 %) 80 (49.1 %) 16 (9.8 %)
Mucinous carcinoma 18 4 (22.2 %) 3 (16.7 %) 11 (61.1 %) <0.001
Endometrioid carcinoma 19 4 (21.1 %) 9 (47.4 %) 6 (31.6 %)
Clear cell carcinoma 11 6 (54.5 %) 4 (36.4 %) 1 (9.1 %)
Mixed epithelial tumor 11 2 (18.2 %) 6 (54.5 %) 3 (27.3 %)
Undifferentiated tumor 5 3 (60.0 %) 1 (20.0 %) 1 (20.0 %)
Unclassified tumor and others 21
FIGO Stage:
I 28 7 (25.0 %) 11 (39.3 %) 10 (35.7 %)
II 18 8 (44.4 %) 6 (33.3 %) 4 (22.2 %)
III 117 47 (40.2 %) 55 (47.0 %) 15 (12.8 %) 0.032
IV 79 31 (38.2 %) 38 (48.1 %) 10 (12.7 %)
Not staged or missing 6
Histological Grade:
Well 19 4 (21.1 %) 9 (47.4 %) 6 (31.6 %)
Moderate 62 20 (32.3 %) 35 (56.5 %) 7 (11.3 %) 0.012
Poor 133 58 (43.6 %) 60 (45.1 %) 15 (11.3 %)
Not graded or missing 34
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(EpCAM), CD133, CD117, CD90 (Thy-1), CD24,
ABCG2, LY6A, AGR5 and ALDH1, etc. [34, 35]. How-
ever, it still remains challenging to identify one single
marker or several combined markers to specifically iden-
tify all the CSCs in ovarian tumor, and the exact roles of
these ‘stemness’ related markers, are still poorly under-
stood due to either a current lack of understanding of
the biological functions of the markers, or frequently the
lack of information correlating the varied isoforms, spli-
cing variants or substrates to stem cell function [34, 35].
ALDH1 is initially found as a cytosolic isozyme located
in the cytoplasm, mainly functioning as the second en-
zyme after alcohol dehydrogenase in the major pathway
of alcohol metabolism in liver. In recent years, soon after
the rise of CSC theory, some specific CSC markers were
being discovered to identify putative CSCs, and ALDH1
is becoming to act as a CSC marker in the CSC studies
of variable tumor types in vitro and in vivo. Epithelial-
to-mesenchymal transition (EMT) is an important driver
of tumor invasion and metastasis, which may be a fea-
ture of CSC. Compared to ALDH1(−) EMT cells, only
ALDH1(+) EMT cells had the ability to initiate a new
epithelial tumor [36]. Both EMT and other CSC proper-
ties of ALDH1(+) lung CSCs can be repressed through
Fibulin3 treatment [14]. Although ALDH1 was vastly
studied as a CSC marker in other solid tumors, it has
been identified as a CSC marker in ovarian carcinoma in
recent years [32]. In their study, dual positive cells of
ALDH1 and another traditional ovarian CSC marker
CD133 were isolated directly from human tumor to ini-
tiate tumor in mice, and these cells displayed enhanced
angiogenesis and tumorigenicity like other CSCs [32].
Moreover, the patients with CD133(+)/ALDH1(+) tumor
cells displayed reduced PFS and OS [32].
Distinct expression levels and patterns of ALDH1 in
various human epithelial cancers and the corresponding
Table 3 The associations of ALDH1 expression levels in stromal cells and the clinical and pathologic characteristics
ALDH1 IHC score in stromal cells p-value
1 (negative) 2 (low) 3 (high)
Number Total N 13 61 174
Age (years old):
≤39 16 0 (.0 %) 5 (31.3 %) 11 (68.8 %)
40–49 41 3 (7.3 %) 10 (24.4 %) 28 (68.3 %) 0.360
50–59 64 2 (3.1 %) 19 (29.7 %) 43 (67.2 %)
60–69 72 6 (8.3 %) 15 (20.8 %) 51 (70.8 %)
≥70 39 1 (2.6 %) 6 (15.4 %) 32 (82.1 %)
missing 16
Histological subtype:
Serous carcinoma 163 6 (3.7 %) 36 (22.1 %) 121 (74.2 %)
Mucinous carcinoma 18 3 (16.7 %) 6 (33.3 %) 9 (50.0 %) 0.077
Endometrioid carcinoma 19 0 (.0 %) 7 (36.8 %) 12 (63.2 %)
Clear cell carcinoma 11 1 (9.1 %) 1 (9.1 %) 9 (81.8 %)
Mixed epithelial tumor 11 0 (.0 %) 4 (36.4 %) 7 (63.6 %)
Undifferentiated tumor 5 1 (20.0 %) 1 (20.0 %) 3 (60.0 %)
Unclassified tumor and others 21
FIGO stage:
I 28 2 (7.1 %) 8 (28.6 %) 18 (64.3 %)
II 18 0 (.0 %) 10 (55.6 %) 8 (44.4 %)
III 117 6 (5.1 %) 27 (23.1 %) 84 (71.8 %) 0.161
IV 79 5 (6.3 %) 14 (17.7 %) 60 (75.9 %)
Not staged or missing 6
Histological grade:
Well 19 1 (5.3 %) 9 (47.4 %) 9 (47.4 %)
Moderate 62 2 (3.2 %) 11 (17.7 %) 49 (79.0 %) 0.655
Poor 133 7 (5.3 %) 34 (25.6 %) 92 (69.2 %)
Not graded or missing 34
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normal tissues were explored [16, 37]. Unlike breast,
lung or colon cancers, ovarian cancer displayed a signifi-
cantly reduced ALDH1 expression compared to benign
tumors and normal ovary [38], indicating a possibly
different role of ALDH1 in ovarian cancer.
Our present immunohistochemical study of 248 well-
characterized patients showed high levels of ALDH1
expression in ovarian carcinoma cells, which were ob-
served in 15.7 % of the total cases, was associated with
early-stage tumor, well-differentiated tumor and better
survivals, although ALDH1 was not an independent risk
factor in multivariate analysis. The patients involved in
the current study were followed up for more than
12 years. To our best knowledge, it is a long follow up
study, which has more predictive meanings in retro-
spective studies.
Our results were similar with a previous immuno-
histochemical study from The University of Texas MD
Anderson Cancer Center. In their long-term follow-up
study, The same mouse monoclonal anti-human ALDH
Clone 44 from BD Transduction Laboratories™ was
used, and it turned out that high level of ALDH1 was
detected in 19 % out of the total 442 ovarian carcinoma
samples, and it was significantly associated with endo-
metrioid adenocarcinoma, early-stage tumor, complete
response to chemotherapy, low serum CA125 level and
Fig. 2 Survival probabilities in different ALDH1 expression groups. a Survival plot disclosed that ALDH1 high expression in tumor cells in ovarian
carcinomas had a better OS than the low expression and Negative groups (p < 0.05, Kaplan-Meier). b High expression level of ALDH1 in tumor
cells in ovarian carcinomas was significantly associated with high PFS probabilities (p < 0.05, Kaplan-Meier). c The expression level of ALDH1 in the
stromal cells in ovarian carcinoma had no significant association with OS probabilities (p > 0.05, Kaplan-Meier). d No statistical association was
found between the expression of ALDH1 in the stromal cells of ovarian carcinoma and the PFS probabilities (p > 0.05, Kaplan-Meier).
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favorable survivals [24]. Similar results were obtained
by immunofluorenscence-based and quantitative ap-
proach in Rimm’s group from Yale University School of
Medicine, a better prognosis in ALDH1(+) patients
with non-small cell lung cancer, using the same primary
antibody with us [39]. Thus, the choice of antibody
may potentially explain the variably predictive and
prognostic role of ALDH1 in human epithelial cancers.
The current antibody we used has been proved specific
and cytoplasmic with homogeneous staining pattern in
different areas from the same case [39]. In this study, the
homogeneously strongly positive cases (with total score 7
and 8) showed a significantly better survival probability.
However, there were other studies indicating a better
clinical outcome in ALDH1(+) cancer patients, using
different antibodies. Our previous study, using rabbit
polyclonal antibody against human ALDH1A1 (ab63026,
Abcam, Cambridge, UK) has proved that ALDH1 ex-
pression in vulvar squamous cell carcinomas predicted a
significantly better survival than the ALDH1 negative
cases [28]. Similarly, Hessman and coworkers, using
antibody from Abcam, Cambridge, found that ALDH1
was highly expressed in early stage colorectal cancer in
contrast with advanced stages [16].
It should be noted that ALDH1 in normal stem cells
has a function of activating cell differentiation through
retinoid acid signaling pathway, and the inhibition of
ALDH1-mediated retinoid signaling impairs human fetal
islet cell differentiation and survival [5]. It is also known
that cancer stem cells share features of normal stem
cells. Therefore, it can’t be excluded in the ovarian can-
cer cells that ALDH1 exerts its role through the same
molecular mechanism, by such contributing to the better
survival in ovarian cancers, although other unknown
molecular mechanisms should be explored.
ALDH1 expression in stromal cells was previously
reported to be frequently and strongly expressed in
both non-malignant and tumor-associated stromal cells
[28, 40–42], which was confirmed in our present study.
However, the potential role of ALDH1 expression in the
tumor microenvironment is rather different in the above
findings. Resetkova et al. hold the opinion that high ex-
pression of ALDH1 in breast cancer stromal cells had a
best disease free survival and a trend of better overall
survival [42], De Brot et al. confirmed that ALDH1
frequent expression in tumor-associated stromal cells of
triple negative breast cancer predicted a better outcome
[41]. On the other hand, Woodward and Ohi together
with their colleages insisted that ALDH1 expression in
stromal cells of breast cancer was not associated to any
clinical outcomes [43, 44]. In the present study, high ex-
pression level of ALDH1 in stromal cells was frequently
observed in ovarian carcinoma, but the expression levels
had no associations with the clinical parameters, and it is
not associated with survival probabilities, which was in
accordance with the findings from Woodward et al. [43]
and Ohi et al. [44].
The current study has several limitations. First of all,
although Allred scoring system combines the percentage
and intensity of positive cells, as a manual scoring
system, it may induce a level of subjectivity, especially
the cut-off points were always a matter of discussion.
Second, histological heterogeneity of ovarian cancers was
not able to be addressed in the present study.
Conclusion
In summary, the current views of ALDH1 predictive role
in ovarian carcinomas remain controversial, and the
present long-term follow-up retrospective study reveals
that high ALDH1 expression in tumor cells portends favor-
able prognosis and better survivals in patients with ovarian
carcinoma, but the expression of ALDH1 in stromal cells
has no associations with clinical outcomes. More studies
are warranted to verify the potential role of ALDH1 in
ovarian carcinoma progression and the molecular mecha-
nisms involved.
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